Ozempic’s India Launch: On December 12, 2025, Danish pharmaceutical giant Novo Nordisk launched its blockbuster diabetes drug Ozempic in India. The Drug Controller General of India (DCGI) granted approval in… Continue Reading
Blogs
Yurpeak (Tirzepatide) by Cipla Now in India for Obesity or Type 2 Diabetes
Cipla Yurpeak (Tirzepatide) Cipla Limited has launched Yurpeak (tirzepatide), a once-weekly injectable therapy for obesity and type 2 diabetes under its marketing and distribution agreement with Eli Lilly and Company… Continue Reading
Gilead’s Yeztugo: A New Era in HIV Prevention
FDA approval for Yeztugo The U.S. FDA has recently approved Yeztugo (lenacapavir), a twice-a-year injectable medication by Gilead Sciences for the prevention of HIV in high-risk individuals. This long-acting drug… Continue Reading
Glenmark Launches Zanubrutinib in India: New Hope in Blood Cancer Treatment
Glenmark Pharmaceuticals to Launch Zanubrutinib for Cancer Treatment in India June 19, 2025 | Mumbai: Glenmark Pharmaceuticals, a leading Indian multinational pharmaceutical company, announced on Monday its plans to launch… Continue Reading
Could Weight Loss Drugs Be the Answer to India’s Growing Obesity Crisis?
Mounjaro Enters India Eli Lilly, the American pharmaceutical giant, announced the launch of its diabetes and weight-loss treatment, Mounjaro (tirzepatide), in India. With approval from India’s Central Drugs Standard Control… Continue Reading